Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

Publisher： Karger

E-ISSN： 1421-9794|56|2|142-146

ISSN： 0009-3157

Source： Chemotherapy, Vol.56, Iss.2, 2010-04, pp. : 142-146

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study

By  

Chemotherapy, Vol. 57, Iss. 2, 2011-03 ,pp. : 138-144

Karger

Access to resources Recommend Favorite

Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer

By  

Chemotherapy, Vol. 61, Iss. 1, 2015-0 ,pp. : 51-56

Karger

Access to resources Recommend Favorite

Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment

By  

Chemotherapy, Vol. 62, Iss. 1, 2016-09 ,pp. : 80-84

Karger

Access to resources Recommend Favorite

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

By Bersanelli Melissa   Buti Sebastiano   Camisa Roberta   Brighenti Matteo   Lazzarelli Silvia   Mazza Giancarlo   Passalacqua Rodolfo  

Cancers, Vol. 6, Iss. 4, 2014-09 ,pp. : 2035-2048

MDPI

Access to resources Recommend Favorite

A Pilot Human Evaluation of a Formulation of Irinotecan and Hyaluronic Acid in 5-Fluorouracil-Refractory Metastatic Colorectal Cancer Patients

By  

Chemotherapy, Vol. 55, Iss. 1, 2008-12 ,pp. : 49-59

Karger

Access to resources Recommend Favorite